BioPharma Credit (BPCR) provides access to a diverse portfolio of debt instruments for life science companies, consisting mainly of senior secured loans at present. Structural changes in the industry and high M&A activity constitute positive drivers of BPCR’s new debt investments. Despite increased life sciences equity and convertible bonds issues, the trust has invested c US$640m so far this year (and has outstanding commitments of US$140.5–160.5m). The trust has recently com
06 Nov 2018
BioPharma Credit - Oversubscribed offering fuels further growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BioPharma Credit - Oversubscribed offering fuels further growth
BioPharma Credit PLC USD (BPCR:LON) | 87.2 0 0.0% | Mkt Cap: 1,093m
- Published:
06 Nov 2018 -
Author:
Milosz Papst -
Pages:
12
BioPharma Credit (BPCR) provides access to a diverse portfolio of debt instruments for life science companies, consisting mainly of senior secured loans at present. Structural changes in the industry and high M&A activity constitute positive drivers of BPCR’s new debt investments. Despite increased life sciences equity and convertible bonds issues, the trust has invested c US$640m so far this year (and has outstanding commitments of US$140.5–160.5m). The trust has recently com